The surgical approach for treating patients with rectal cancer has evolved from the perineal resection to sphincter-saving surgery so as to decrease local recurrence and to preserve organs. Along with surgical advances such as the total mesorectal excision (TME), the introduction of chemoradiotherapy (CRT) has significantly lowered the local recurrence rate from 15%–20% to 4%–5% [1]. However, the TME with CRT is associated with a mortality rate of 1%–4% and a morbidity, including bowel and urogenital dysfunction, rate of ~40%. The postoperative morbidity associated with the TME and the good oncologic outcomes in downstaged patients after CRT have raised questions regarding the utility of a mesorectal resection.

Local excision after CRT can be posited as an option for good responders with locally advanced rectal cancers so as to preserve the rectum and to achieve a local recurrence comparable to that of the TME. A sequential 2-stage phase II study was performed with 63 patients, and the 3-year disease-free survival was 91% [2]. According to the GRECCAR 2 randomized trial for patients with clinical stage II to III rectal cancer, of the good clinical responders who underwent long-course CRT, 46% had a chance of rectal preservation (presented in American Society for Radiation Oncology 2014). In Lee et al. [3]'s study, 2 of the 35 patients who underwent transanal minimally invasive surgery (TAMIS) had local recurrences without distant metastasis, and complete salvage could be achieved for one patient.

TAMIS, a technique developed in 2009 [4], has several advantages over conventional transanal local excision or transanal endoscopic microsurgery (TEM). The main benefits are a wide and clear view of the tumor, a short setup time, use of familiar laparoscopic instruments, a wide range of motion, a freely movable camera, and applicability to the proximally located rectal tumors. Moreover, TAMIS is a cost-effective alternative to the TEM [4]. Lee et al. [3] attempted to apply this relatively new technique for local excision in good responders with locally advanced rectal cancer after CRT, a course of treatment that has been highly debated recently. While concerns regarding the oncologic outcomes of local excision after CRT are still present, this study demonstrates the technical and oncological feasibility of TAMIS for patients eligible for local excision, even after CRT. Further investigations should be conducted to select patients who could benefit from TAMIS after CRT.